Cybin (NYSE:CYBN) (NYSE:CYBN) is a clinical-stage biopharmaceutical company focused on researching, developing and commercializing novel proprietary psychedelic-based compounds for the treatment of mental health disorders. Founded in 2019 and headquartered in Toronto, Canada, Cybin has established operations in North America and Europe to advance its drug discovery efforts and build a diverse pipeline. The company leverages medicinal chemistry, formulation engineering and drug delivery technology to optimize the therapeutic potential of classical psychedelics such as psilocybin and DMT.
At the core of Cybin’s strategy is its multi-portfolio approach to address conditions including major depressive disorder, anxiety and sleep disturbances. The company’s proprietary platforms include deuterated psilocybin derivatives designed to enhance pharmacokinetic profiles, as well as oral thin-film and sublingual formulations aimed at improving patient experience and dosing convenience. Cybin’s patent-protected drug delivery systems seek to reduce variability in absorption and mitigate common challenges associated with conventional psychedelic administration.
Cybin’s clinical pipeline features several candidates in early- and mid-stage trials. A lead drug candidate is being evaluated in Phase 1 and Phase 2 studies for depression, while additional programs target social anxiety disorder and alcohol use disorder. Through partnerships with academic institutions, clinical research organizations and specialty clinics across Canada, the United States, the United Kingdom and Ireland, Cybin is advancing a global trial network to generate evidence supporting regulatory approvals.
Leadership at Cybin comprises seasoned executives with deep experience in biotechnology, pharmaceuticals and consumer products. Doug Drysdale, who joined as Chief Executive Officer in 2021, oversees corporate strategy and clinical development. The executive team includes Chief Scientific Officer Dr. Patrick Wilkinson, who leads drug discovery initiatives, and Chief Financial Officer Denis Davidson, responsible for corporate finance and investor relations. Together, the management group is tasked with translating psychedelic research into scalable therapeutic solutions for mental health care.
